A Syngeneic Orthotopic Murine Model of Pancreatic Adenocarcinoma in the C57/BL6 Mouse Using the Panc02 and 6606PDA Cell Lines by Partecke, L.I. et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Eur Surg Res 2011;47:98–107 
 DOI: 10.1159/000329413 
 A Syngeneic Orthotopic Murine Model of 
Pancreatic Adenocarcinoma in the C57/BL6 Mouse 
Using the Panc02 and 6606PDA Cell Lines  
 L.I. Partecke  a    M. Sendler  b    A. Kaeding  a    F.U. Weiss  b    J. Mayerle  b    A. Dummer  b    
T.D. Nguyen  a    N. Albers  a    S. Speerforck  a    M.M. Lerch  b    C.D. Heidecke  a    
W. von Bernstorff  a    A. Stier  c   
 Departments of  a   General, Visceral, Thoracic and Vascular Surgery, and  b   Gastroenterology and Nephrology,
Ernst Moritz Arndt University,  Greifswald , and  c   Department of Surgery, Helios Clinic,  Erfurt , Germany
 
more spherically. Both tumors showed local invasiveness. 
Histologically, Panc02 showed a sarcoma-like undifferenti-
ated growth pattern, whereas 6606PDA displayed a moder-
ately differentiated glandular tumor growth. Panc02 mice 
had a significantly shorter (28 days) survival than 6606PDA 
mice (50 days).  Conclusion: This model closely mimics hu-
man pancreatic cancer. MRI was invaluable for longitudinal 
monitoring of tumor growth thus reducing the number of 
mice required. Employing two different cell lines, this model 
can be used for various treatment and imaging studies. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Pancreatic cancer is the fourth leading cause of can-
cer death in the Western hemisphere. Its annual inci-
dence is steadily rising and it is responsible for approxi-
mately 33,000 cancer deaths in the United States and 
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 Abstract 
 Background/Aims: To develop a clinically relevant immuno-
competent murine model to study pancreatic cancer using 
two different syngeneic pancreatic cancer cell lines and to 
assess MRI for its applicability in this model.  Methods: Two 
cell lines, 6606PDA and Panc02, were employed for the ex-
periments. Cell proliferation and migration were monitored 
in vitro. Matrigel TM was tested for its role in tumor induction. 
Tumor cell growth was assessed after orthotopic injection
of tumor cells into the pancreatic head of C57/BL6 mice by 
MRI and histology.  Results: Proliferation and migration of 
Panc02 were significantly faster than those of 6606PDA. 
Matrigel did not affect tumor growth/migration but pre-
vented tumor cell spread after injection thus avoiding un-
desired peritoneal tumor growth. MRI could reliably moni-
tor longitudinal tumor growth in both cell lines: Panc02
had a more irregular finger-like growth, and 6606PDA grew
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almost 13,000 in Germany  [1–3] . The late onset of symp-
toms, early development of metastases and the high 
morbidity associated with surgery add to its often rapid 
and fatal course. This is mirrored by diagnoses usual-
ly made in late stages of disease as well as the general 
lack of effective adjuvant and palliative treatment op-
tions  [4] .
 At the cellular as well as the molecular level, several 
mechanisms have been described that enable the cancer 
cell to evade the surveillance of the immune system. 
These include the loss of co-stimulatory molecules such 
as ICAM-1 or B-7  [5–7] or the loss of functional death 
receptors like Fas  [8, 9] . Pancreatic cancer cells may also 
actively suppress the immune response by factors like IL-
10, glycoproteins or FasL  [8–12] . Furthermore, IL-10 and 
TGF-  are elevated in sera of pancreatic cancer patients 
and could induce a general state of immunosuppression. 
This may promote tumor growth and the formation of 
disseminated disease as evidenced by disseminated tu-
mor cells in  1 40% of cancer patients  [13] .
 Despite the advances in cancer immunology and im-
provement in surgical as well as non-surgical therapeutic 
approaches in patients with metastases  [14] ,  the overall 
5-year survival rate of 5% has not changed significantly 
 [3] . Hence, models that resemble the human situation in 
pancreatic cancer are required to study the underlying 
causes of immunosuppression. Also, these models can be 
helpful in developing new preclinical treatment modali-
ties hopefully leading to effective therapies against pan-
creatic cancer. Here, we introduce a syngeneic orthotopic 
murine model using two different murine pancreatic ad-
enocarcinoma cell lines: the well-differentiated, slowly 
growing modestly aggressive cell line 6606PDA and the 
low/undifferentiated fast growing highly aggressive cell 
line Panc02. For longitudinal studies of tumor growth, a 
7-tesla MRI scan was employed.
 Materials and Methods 
 Laboratory Animals 
 Eight-week-old male C57/BL6 mice with a body weight of 20–
23 g were obtained from the Charles River Laboratories (Bad Sulz-
feld, Germany) and allowed to adapt to the new surrounding for 
14 days. They were maintained in a specific pathogen-free envi-
ronment receiving sterilized food (ssniV R-Z, ssniV Spezialdiäten 
GmbH, Soest, Germany) and tap water ad libitum. Stress levels 
were kept to a minimum before being used in experiments. Ani-
mal rooms had a 12-hour light/dark cycle and were maintained at 
constant temperature and humidity. All animal studies had been 
approved by the Ethics Committee for Animal Care of Mecklen-
burg-Vorpommern, Germany.
 Cell Lines and Culture 
 The murine pancreatic adenocarcinoma cell line 6606PDA, 
containing a K-ras G12D mutation, was a kind gift from Prof. Tu-
veson, Cambridge, UK. The murine pancreatic adenocarcinoma 
cell line Panc02 was developed by Corbett et al.  [15] . 6606PDA was 
maintained in RPMI-1640 medium and Panc02 in DMEM. Both 
media were supplemented with 10% fetal calf serum, 100 U/ml of 
penicillin and 100   g/ml of streptomycin (referred to as ‘complete 
medium’). Tissue culture reagents were obtained from Gibco (In-
vitrogen, Carlsbad, Calif., USA). Cell cultures were kept in a hu-
midified incubator at 37  °  C with 5% CO 2 .
 Orthotopic Injection of Tumor Cells 
 Subconfluent cultures of tumor cells were harvested using a 
0.05% trypsin solution, washed twice in PBS and resuspended as 
single-cell suspensions in serum-free RPMI-1640 or DMEM. Cell 
viability was tested using trypan blue exclusion. Viability was al-
ways  1 95%.
 General anesthesia in mice was induced using a combination 
of ketamine hydrochloride (Ketanest S  ; Pfizer Pharma, Berlin, 
Germany) and xylometazoline hydrochloride (Rompun  ; Bayer 
Healthcare, Berlin, Germany) at concentrations of 87 and 13 mg/
kg i.p. The abdominal cavity was opened by a 1.5-cm-wide trans-
verse laparotomy pointing slightly to the right. The head of the 
pancreas was identified and lifted up by a cotton wool tip. Injec-
tions ( fig. 1 ) were carried out in two different groups to test for 
differences in local spread and the formation of local extrapan-
creatic tumors due to tumor cell spread. One group received 2.5 
 ! 10 5 viable tumor cells in 20   l of ice-cold PBS. The second 
group received 2.5  ! 10 5 viable tumor cells in 20   l of ice-cold 
Matrigel TM (BD Bioscience, San José, Calif., USA). Matrigel is a 
substance with a more watery consistency at 4  °  C but turns into a 
gel-like substance when reaching temperatures  1 22   °   C. It was 
used to prevent local spread and thereby the early development of 
local peritoneal tumor growth.
 Fig. 1. Technique of tumor cell injection into the head of the pan-
creas using Matrigel. 
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 Tumor cells were slowly injected into the head of the pancreas 
using a pre-cooled 27-gauge needle and a pre-cooled calibrated 
special syringe (Hamilton Syringe, Reno, Nev., USA). To further 
prevent leakage, a cotton wool tip was pressed onto the injection 
site for 30 s. To ensure the same injection technique for all exper-
iments, the injection was always carried out by the same person 
(M.S.). The pancreas was then placed back into the abdominal 
cavity. The abdominal cavity was closed by a running single-layer 
4-0 polyester suture (Catgut, Markneukirchen, Germany). To de-
crease postsurgical pain and the effects of surgery, we subcutane-
ously injected buprenorphine hydrochloride at a dose of 0.1 mg/
kg. So far, we have not had any fatalities related to surgery.
 Observation Period, Assessment of Tumor Size and Survival 
 All mice were checked daily for their general condition and 
twice weekly for tumor formation. In case of severe tumor disease 
or another form of mice were sacrificed by ether narcosis and cer-
vical dislocation. Necropsies were carried out on all of these ani-
mals immediately after sacrifice. Sites of obvious or potential tu-
mor growth, including the pancreas, the liver, peritoneal lymph 
nodes as well as other suspicious tissue, were harvested and rou-
tinely processed for histologic microscopic examination.
 Ten and 21 days after tumor injection, animals were scanned 
for tumor growth using a 7-tesla small-animal MRI scan. Sur-
vival analyses were performed using the Kaplan-Meier procedure.
 7-Tesla Small-Animal MRI 
 For MRI experiments, anesthesia was induced by isoflurane 
(1–1.5%). Thereafter, all mice were kept in a supine position. High-
power–field, 7.0-tesla MRI for small animals (Bruker, ClinScan, 
7.0 T, 290 mT/m gradient strength; Karlsruhe, Germany) was per-
formed and analyzed in a whole mouse body coil (Bruker) using 
a T 2 -TSE sequence. The whole body coil is a volume coil and al-
lows imaging of the whole mouse without inducing any inhomo-
geneities of the signal. For the assessment of tumor size, we used 
high-resolution T 2 -weighted images in the frontal and the hori-
zontal plane (frontal: TR: ca. 1,200 ms; TE: 41.0 ms; FA: 180°; FoV: 
42 mm  ! 42 mm; matrix: 240  ! 320; 24 slices of 0.7 mm per slice, 
acquisition time: ca. 15 min ; horizontal: TR:   1,250 ms; TE: 41.0 
ms; FA: 180°; FoV: 40 mm  ! 40 mm; matrix: 240  ! 320; 24 slic-
es of 0.7 mm per slice, acquisition time: ca. 10 min). Generated 
images were analyzed employing MIPAV (medical imaging pro-
cessing and visualization), a special DICOM-software of the Na-
tional Institutes of Health, Bethesda, Md., USA. All image slices 
of the tumors were marked with so-called regions of interest, 
which facilitated the calculation of the tumor volume.
 In vitro Studies of Tumor Cells in Matrigel 
 Matrigel has been used in several experimental settings. Here, 
we assessed its role as a solvent in tumor cell injections into the 
pancreas to prevent local spread and thereby the early develop-
ment of unintentional local peritoneal tumor growth. Matrigel is 
a substance with a more watery consistency at 4  °  C but turns into 
a gel-like substance when reaching temperatures  1 22   °   C. After 
orthotopic tumor cell injection into the mouse pancreas, it was 
expected to change into a gel thereby blocking the injection canal 
and minimizing the risk of local spread. To exclude a significant 
influence of Matrigel onto the viability and migration of tumor 
cells, we first analyzed tumor cell viability and migration in vitro. 
Viability was tested by simple trypan blue exclusion.
 Subconfluent cultures of Panc02 or 6606PDA tumor cells were 
harvested as above and washed twice in ice-cold PBS. Thereafter, 
cells were counted and 1  ! 10 6 cells were resuspended in 80   l of 
ice-cold PBS. The cell suspension was added to 80   l of ice-cold 
Matrigel solution and gently mixed for 1 min. Portions of 20   l of 
this cell suspension were plated in 10-cm culture dishes, and cell 
adherence was allowed for 10 min in a humidified incubator at 
37   °  C. Then, 10 ml of pre-warmed complete medium were added 
to these cultures. Control cultures were prepared without Matri-
gel. After complete adherence of tumor cells, the margin of tumor 
cells within the Matrigel as well as the margin of the Matrigel were 
marked with a marker on the outside of the dish. Similar marks 
were made on the non-Matrigel cultures to compare migration 
without Matrigel. Differences in migration were measured in mil-
limeters and were calculated using the following formula: differ-
ence in migration = distance in migration (control) – distance in 
migration (Matrigel).
 All experiments were done in triplicate, and results were cal-
culated as means of all experiments. Cell migration was visual-
ized using a fluorescence binocular microscope (Leitz, Wetzlar, 
Germany).
 CellTiter-Blue TM Viability Assay 
 Cell proliferation was assessed using the CellTiter-Blue (CTB) 
viability assay (Promega, Madison, Wisc., USA). Pancreatic cancer 
cells were seeded at a concentration of 5  ! 10 3 cells/well in 96-well 
plates in 100   l of complete medium. Three duplicate wells were 
set up for each group. Blank wells with complete medium only 
served as negative controls. Proliferation was measured after 24 h 
by adding 20   l of CTB reagent per well followed by a 1-hour in-
cubation under standard cell culture conditions. Absorbance of 
each well was measured on a microplate fluorescence reader with 
an excitation of 560 nm and an emission of 590 nm.
 In vitro Wounding Assay (Scratch Assay) 
 This test was performed largely following the protocol of Liang 
et al.  [16] . Briefly, tumor cells were cultured until reaching con-
fluency. Injury of the confluent monolayer was done by a scratch 
in the middle of the culture with a standard 200-  l pipette tip. 
The injured monolayers were washed twice with PBS to remove 
non-adherent cells. Further proliferation was inhibited by adding
1 m M of mitomycin solution (Sigma-Aldrich, Munich, Germany) 
dissolved in complete medium followed by a 1-hour incubation 
period. Wound closure was monitored using an inverted phase-
contrast microscope (Leica, Wetzlar, Germany). Two indepen-
dent series of experiments were performed. Migration of tumor 
cells into the scratched lesion, i.e. wound closure, was calculated 
using the formula:  (X-hour value – 0-hour value)/(100 – 0-hour 
value) = relative migration front proportional to the initial scratch 
magnitude.
 Histology 
 Tumor-bearing animals were sacrificed after the final MRI 
examination. The pancreas including the tumor was completely 
resected. The complete specimens were fixed in 10% buffered for-
malin, processed routinely, embedded in paraffin and cut into 
4-  m sections using a microtome (Leica). Sections were then 
mounted onto glass slides coated with poly- L -lysine (Karl Roth 
GmbH, Karlsruhe, Germany), baked at 60   °   C for 1 h and cooled 
overnight. Sections were deparaffinized in xylene and washed in 
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100% alcohol. Then, sections were washed in phosphate-buffered 
saline (PBS) at pH 7.4, followed by staining with hematoxylin un-
til the desired staining was reached. Sections were rinsed in tap 
water for 20 min, washed in PBS followed by the second staining 
protocol using eosin until the desired staining was reached. Af-
terwards, sections were rinsed in tap water for 20 min, cleared and 
coverslipped.
 The sections were then examined using a Leica light micro-
scope.
 Statistical Analysis 
 In vitro and in vivo results were statistically analyzed using the 
program GraphPad InStat, version 3.06 (GraphPad Software Inc., 
San Diego, Calif., USA). The unpaired or the paired t test with 
Welch’s correction or the unpaired Mann-Whitney test (for non-
Gaussian distribution) was employed to compare mean values of 
the experiments. A p value  ! 0.05 was considered to be statisti-
cally significant.
 Results 
 Determination of the Optimal Matrigel Concentration 
for in vivo Injection 
 In several dilution series, the optimal ratio of the PBS 
tumor cell suspension to Matrigel was found to be 1: 1. 
When increasing the Matrigel, the solution became more 
viscous. This made the injection into the pancreatic tis-
sue more difficult due to too fast jellification. Lower con-
centrations of Matrigel down to 3: 1, as they are common-
ly used for the preparation of in vitro basal membranes, 
led to more fluid solutions that were not effective in pre-
venting leakage and local tumor cell dissemination at the 
injection site.
 Handling of Matrigel Cell Suspensions 
 The handling of Matrigel itself and Matrigel tumor 
cell suspensions posed no difficulties as long as the Matri-
gel was continuously kept on ice. Injection of the ice-cold, 
liquid, single-cell suspension was facilitated using pre-
cooled 27-gauge needles and a pre-cooled calibrated 25-
  l Hamilton syringe (Hamilton, Reno, Nev., USA).
 Proliferation and Migration of Tumor Cells in vitro 
 To exclude a negative impact of Matrigel on tumor 
cells, their proliferation and migration in Matrigel were 
observed in vitro using a light microscope. Within 24 h, 
tumor cells had proliferated significantly and had already 
evaded the Matrigel margins ( fig. 2 ). Further observation 
could not detect any negative effect of Matrigel either on 
proliferation or on migration of tumor cells.
 Scratch Assay 
 Comparing migration of the cell lines Panc02 and 
6606PDA, Panc02 migrated significantly (p  ! 0.018) fast-
er into the scratch. This was clearly visible after 24 h; after 
36–48 h, the scratch was completely covered. 6606PDA 
also showed visible migration but even after 48 h there 
was still a considerable distance left between the two 
margins of migrating tumor cells ( fig. 3 ).
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 Fig. 2. Panc02 tumor cells evading Matrigel 36 h following seed-
ing. 
 Fig. 3. Scratch assay: after 48 h, the Panc02 scratch was almost 
closed whereas the 6606PDA scratch was closed only about 60% 
(relative value). 
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 Proliferation Assay (CTB Viability Assay) 
 Panc02 cells proliferated significantly (p = 0.0071) 
faster than 6606PDA cells within 24 h: seeding of 5  ! 10 3 
tumor cells resulted in 11,346 Panc02 cells and in 8,391 
6606PDA cells after 24 h of incubation, i.e. in vitro Panc02 
cells grew 1.87 times faster than 6606PDA cells ( fig. 4 ), 
approximating a doubling time of 18 h for Panc02 cells 
and 35 h for 6606PDA cells.
 Tumor Growth Monitored by MRI 
 The pancreatic cancer cell line Panc02 developed sig-
nificantly larger tumors compared to 6606PDA tumors. 
Ten days after tumor injection, Panc02 tumors had a 
mean volume of 131 mm 3 ( 8 52 mm 3 ) whereas 6606PDA 
tumors had a mean volume of 36 mm 3 ( 8 6 mm 3 ); 21
days after tumor injection ( fig. 5 ), Panc02 tumors had in-
creased to a mean volume of 1,475 mm 3 ( 8 406 mm 3 ). 
6606PDA tumors showed mean volumes of only 540 mm 3 
( 8 219 mm 3 ). Also, 21 days after tumor injection, in 4 of 5 
animals Panc02 tumors had induced hemorrhagic ascites. 
In 3 of 5 Panc02-injected mice, a distended gallbladder 
combined with biliary duct obstruction was found. The 
latter was seen only rarely in 6606PDA tumors and hem-
orrhagic ascites was absent in 6606PDA tumors.
 Macroscopic tumor growth was also different. Panc02 
showed more invasive, finger-like MRI images also dis-
playing a more irregular disseminated pattern ( fig.  6 ). 
6606PDA MR images resembled more a spherical growth 
pattern, often showing a central zone of necrosis. How-
ever, both tumors were locally invasive.
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 Fig. 4. Proliferation of tumor cells after 24 h of incubation (CTB 
assay; cell proliferation after 24 h).  * *  p  ! 0.0071. 
 Fig. 5. Increase in tumor size 3 weeks after implantation of Panc02 
versus 6606PDA ( * * *  p  ! 0.0001). 
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 Fig. 6. MRI scans of 6606PDA ( a ) and 
Panc02 tumors ( b ). Of note: 6606PDA tu-
mors showed a more compact globe-like 
tumor growth often with a central zone of 
necrosis ( a ). Panc02 tumors showed a 
more irregular lobulated growth pattern 
( b ) with central necroses less frequently 
seen than in 6606PDA tumors. Both tu-
mors show local signs of invasion (arrows). 
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 Metastatic lesions to the liver or lung have only rarely 
been noticed in either tumor entity during MRI analyses 
(4%, i.e. in 2/50 mice). However, invasion of neighboring 
organs such as the liver, small and large bowel, and stom-
ach did occur in about 30% of mice (i.e. 14/50 mice,  fig. 6 ). 
In these cases, MRI scans were highly suggestive of local 
tumor invasion due to the excellent high local resolution 
of MRI down to differences of 0.1 mm in size. This could 
later be confirmed by histological sections of the areas of 
interest.
 Survival of Mice 
 Median survival of mice injected with Panc02 cells 
was 28 days (Kaplan-Meier survival curve:  fig. 7 ). In con-
trast, mice injected with 6606PDA cells displayed a me-
dian survival of 50 days. This difference was statistically 
highly significant, p  ! 0.0001. Animals bearing Panc02 
tumors usually died of local complications such as ileus 
and/or bile duct obstruction. This was mainly due to the 
rapidly growing tumors cells. In Panc02 mice without us-
ing Matrigel ( fig.  8 ), survival was significantly shorter 
than in mice injected with tumor cells suspended in 
Matrigel (20.0 vs. 25.5 days, p = 0.0012). This was again 
due to increased peritoneal tumor spread during and/or 
after injection.
 Macroscopic and Microscopic Pathology 
 Both cell lines reproducibly formed orthotopic tumors 
in the head of the pancreas. 6606PDA tumors displayed a 
more compact globe-like growth pattern whereas Panc02 
showed a more irregular lobulated growth pattern ( fig. 9 ). 
Both tumor lines were locally invading surrounding tis-
sues. However, we did not detect the regular formation of 
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 Fig. 7. Survival of mice bearing Panc02 (median 28 days) versus 
6606PDA (median 50 days;  * * *  p  ! 0.0001). 
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 Fig. 8. Survival of mice injected with Panc02/PBS versus Panc02/
Matrigel. 
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 Fig. 9. Macroscopic pathology of 6606PDA ( a ) and Panc02 ( b ). Of 
note: 6606PDA tumors showed a more compact globe-like growth 
pattern ( a ), whereas Panc02 demonstrated a more irregular lobu-
lated growth pattern ( b ). 
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distant metastases, particularly of the liver. Lymph node 
metastases were often seen in both cell lines, albeit Panc02 
showed lymph node metastases more frequently than 
6606PDA. Microscopic analysis ( fig. 10 ) showed moder-
ately/well-differentiated pancreatic 6606PDA tumors 
with duct-like structures in many cases. These tumors re-
sembled the growth pattern of many human pancreatic 
adenocarcinomas. In marked contrast, Panc02 tumors 
formed poorly differentiated/undifferentiated tumors 
displaying a sarcoma-like growth pattern. However, in 
both tumors strong infiltration with leukocytes could be 
observed.
 Discussion 
 In this study, we present a murine orthotopic pancre-
atic cancer model using two different cell lines in immu-
nocompetent C57/BL6 mice. It can be used for several 
purposes, e.g. to study new therapeutic agents as well as 
to analyze the effects of tumor growth on the immune 
system. At the same time, tumor growth and lymph node 
metastasis formation can be monitored employing a 
small-animal MRI.
 In the past, several tumor models have been intro-
duced for the study of pancreatic cancer. In the 1970s, 
human cancer tissue was first implanted subcutaneously 
into nude mice. This was later followed by orthotopic 
cancer tissue implantation  [17] . After establishing a grow-
ing number of human pancreatic cancer cell lines, these 
were implanted subcutaneously  [18, 19] as well as ortho-
topically  [20] . However, subcutaneous inoculation lacks 
many features present in human tumors, including inva-
sive and metastatic behaviors. This is most likely a result 
of differences in the microenvironment in the subcutis 
compared with the original milieu, which also results in 
an altered drug response in subcutaneous tumor models 
 [21] . Therefore, orthotopic tumor models, including or-
thotopic transplantation of human tumor from surgical 
specimens, appear to be more advantageous for preclini-
cal studies of tumor development, metastasis formation 
and response to treatment. These techniques have also 
been used for other cancer models, including colon can-
cer  [22] . Orthotopic transplantation enables the interac-
tion of tumor cells with organ site-dependent microenvi-
ronmental factors, e.g epidermal growth factor and vas-
cular endothelial growth factor, which can modulate 
tumor growth patterns, progression and metastatic po-
tential  [23, 24] . However, these models still lack immune 
cell-tumor cell interactions since human tumor cells were 
transplanted as xenografts into immunodeficient mice. 
Syngeneic orthotopic murine tumor models avoid these 
500 µm
a
500 µm
b
 Fig. 10. Microscopic pathology of 6606PDA ( a ) and Panc02 ( b ). Of note: 6606PDA tumor cells display a more 
duct-like differentiation ( a ) whereas Panc02 tumor cells reveal a more sarcomatous growth pattern ( b ). Both 
tumors show invasion of the surrounding tissue. 
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short comings. They appear to be the best preclinical 
models for studying the interaction of tumor cells with 
the host immune system as well as the impact of tumors 
on other local and systemic factors, including the sur-
rounding tissue and the vascular system. A functioning 
immune system is the backbone of studies involving cy-
totoxic T cells, regulatory T cells, tumor-associated M2 
macrophages, cell trafficking or the inflammatory fibrot-
ic stromal reaction. Furthermore, immunocompetent 
models appear to be most suitable for all therapeutic 
studies, including studies on the route of administration 
of therapeutic agents  [25, 26] . The development of syn-
geneic murine pancreatic cancer cell lines like Panc02
or 6606PDA paves the way for these models. The Panc02 
cell line was established by Corbett et al.  [15] by inject-
ing 3-methyl-cholanthrene into the pancreas of C57/
BL6 mice. It represents the most widely used cell line. 
6606PDA cells were isolated by Tuveson et al.  [27] from 
p48/Kras G12D mice. Both cell lines represent two differ-
ent forms of differentiation. Panc02 displays a more un-
differentiated growth pattern, showing a significantly 
more aggressive and invasive behavior than 6606PDA, 
which is reflected by a faster doubling time, faster migra-
tion in scratch assays and a significantly shorter survival 
of mice, as presented here. In contrast, the growth pattern 
of 6606PDA cells shows well/moderate differentiation of 
tumor cells on histology. Pancreatic acinus- and duct-like 
structures are commonly found. Yet, both cell lines show 
typical signs of malignant cells, e.g. uncontrolled cell 
growth and local invasion of surrounding tissues. It de-
pends on the purpose of the researcher which cell line 
should be used in experiments. If a fast-growing, less-
differentiated, more-aggressive cell is required, Panc02
is the cell line of choice. If the study requires a slower-
growing, more-differentiated, less-aggressive cell, then 
6606PDA is the preferred cell line. However, neither cell 
line has displayed the reliable formation of distant liver 
or lung metastases. This might be due to a possible late 
formation of distant metastases. In this scenario, the 
mouse may not live long enough to experience metastases 
but succumbs to the initially implanted tumor  [23] . After 
developing murine models to resect pancreatic cancer, 
this issue should be further explored.
 If liver metastases are required, the splenic injection 
technique offers a suitable model  [28] . For lung metasta-
ses, the injection of tumor cells via the tail vein is an es-
tablished method  [19] .
 Subcutaneous injection of tumor cells is fairly easy to 
learn and perform. The injection itself can be done with-
out any narcotics. In contrast, orthotopic injection of 
pancreatic cancer cells requires a highly skilled tech-
nique. First, the implantation is only possible via lapa-
rotomy during anesthesia. Second, in contrast to the 
 human pancreas, the murine pancreas is a soft mobile in-
traperitoneal organ. Third, injections into the tail, the 
corpus or the head of the pancreas are all feasible, but due 
to the size and organ texture require a skilled technique. 
Also, the risk of tumor cell spread after removing the in-
jection needle is high. Tumor cell spread can cause early 
unwanted complications like falsely resembling perito-
neal metastases. These can induce early ileus leading to 
an undesired bias in mortality rates. To avoid the afore-
mentioned problems, we suggest the injection to be done 
by a very limited number of trained personnel, preferably 
by only one or two. In addition, instead of injecting com-
monly used liquids for tumor cell suspensions, e.g. PBS 
or HBSS, our results suggest to suspend tumor cells in 
Matrigel solutions  [29] . As shown in this study, the de-
scribed injection technique including the use of Matrigel 
significantly improved survival of mice injected with 
pancreatic cancer cells. This ensures reproducible ortho-
topic tumor growth as well as prolonged and comparable 
survival of mice.
 Employing orthotopic tumor models has also brought 
up the need for in vivo monitoring of tumor development 
and possible metastasis formation. Tumors of subcutane-
ous models can easily be monitored by simple palpation 
or the use of calipers. For orthotopic tumor models, sev-
eral in vivo murine imaging systems, including MRI, CT, 
CT-PET, ultrasound, as well as bioluminescence and flu-
orescence imaging techniques, have been developed to 
assess tumor size and volume  [30] . These techniques have 
dramatically reduced the number of animals required 
since each animal can be scanned repeatedly in a longi-
tudinal study, avoiding the need for large control groups. 
However, the MRI technique combines several advantag-
es, making it the preferred imaging technique. MRI offers 
better discrimination of soft tissue and local resolution 
 [31] . It also presents a broader spectrum of dynamically 
contrast-enhanced scanning options and can, in contrast 
to fluorescence techniques, image the complete animal 
 [32] . Also, the experimental setup as well as the MRI tech-
nique itself allows imaging using contrast media, scan-
ning the animal for longer periods and allowing repeated 
imaging series. Finally, MRI does not employ any radia-
tion and, in contrast to ultrasonography, is less investiga-
tor dependent  [33] . In the present study, tumor volumes 
could be determined without any problems. The detec-
tion of lymph nodes, of hemorrhagic ascites and cholesta-
sis was possible. The high spatial resolution of MRI en-
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Eur Surg Res 2011;47:98–107106
abled us to detect changes as small as 0.1 mm. Thus, tu-
mor infiltration, e.g. of the bowel, could be noted on MRI 
or MR changes were highly suggestive of tumor infiltra-
tion. These observations were confirmed by histological 
analyses at the end of tumor studies, and results proved 
that MRI is an indispensable tool for monitoring in vivo 
tumor growth in longitudinal studies, thus reducing the 
number of research animals.
 In summary, the model presented closely mimics the 
clinical situation of human pancreatic cancer. The num-
ber of research animals can be significantly reduced in 
longitudinal studies. Employing two different cell lines, 
it can be used for imaging studies as well as non-surgical 
and surgical treatment purposes.
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